Momelotinib for VEXAS syndrome
Part of Blood & lymphatic clinical trials.
This trial tests a drug called momelotinib for people with VEXAS syndrome, a rare inflammatory condition. The goal is to see if momelotinib can reduce symptoms and the need for steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of VEXAS syndrome with a UBA1 gene mutation.
- You should be taking at least 10 mg of prednisone (or a similar steroid) daily for symptoms.
- You cannot have previously taken a JAK inhibitor drug (like ruxolitinib) for any reason.
- Your liver and kidney function should be adequate based on blood tests.
- You must be at least 18 years old and have a performance status of 0–2 (able to care for yourself).
- Women who can become pregnant must use effective contraception and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug momelotinib can safely reduce inflammation and improve symptoms in people with VEXAS syndrome, a rare genetic condition. Participants will keep taking their usual steroids and may receive momelotinib or a placebo to see if it helps control the disease.
This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This study tests an investigational drug called arumakimig (MAS825) in people with VEXAS, a rare genetic condition that causes inflammation. The trial checks if the drug helps control symptoms and improve quality of life.
This trial tests a combination of two drugs, momelotinib and a hypomethylating agent, for people with certain slow-growing blood cancers. If you have a diagnosis like chronic myelomonocytic leukemia or chronic neutrophilic leukemia and have an enlarged spleen, this study might be exploring a new treatment option for you.
This trial combines two drugs, bomedemstat and momelotinib, to treat myelofibrosis, a rare blood cancer. It aims to see if the combination helps improve blood counts and reduce symptoms when momelotinib alone isn't working well enough.
Hear when a new VEXAS Syndome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.